Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US4975369A · kind A · utility
102Cited by
1References
77Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 1988 |
| Grant date | Dec 4, 1990 |
| Priority date | — |
| Expiry date | Apr 21, 2008 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.